Scharf Investments’s AbbVie ABBV Stock Holding History

Scharf Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-61,175	Closed	-$6.01M	–	40
2020 Q2	$6.01M	Buy	+61,175	New	+$5.39M	0.27%	26

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Scharf Investments's ABBV Position: Q3 2020 in Review

Scharf Investments sold out of AbbVie (ABBV) in Q3 2020, closing a stake of 61,175 shares — an estimated $6.01M sold.

Scharf Investments first reported a position in ABBV in Q2 2020 and held it in 1 quarter. The position peaked at $6.01M in Q2 2020. 2,366 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

Scharf Investments reported no remaining AbbVie position as of Q3 2020 after selling out during the quarter.
Scharf Investments sold 61,175 AbbVie shares in Q3 2020, an estimated $6.01M.
Scharf Investments first reported a position in AbbVie in Q2 2020 and held it in 1 quarter.
Scharf Investments's AbbVie position peaked at $6.01M in Q2 2020.
2,366 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on Scharf Investments's 13F filing for Q3 2020, filed 19 Oct 2020.